SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

December 08, 2010 08:45 ET

Radient Pharmaceuticals Onko-Sure® In Vitro Diagnostic Cancer Test Potentially Effective as Veterinary Cancer Tumor Marker

TUSTIN, CA--(Marketwire - December 8, 2010) - Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) today announced it has completed a pilot clinical study to measure the feasibility of using its Onko-Sure® in vitro diagnostic (IVD) cancer test kit as a veterinary tumor marker initially for cancer detection in domestic cats.

Preliminary data from the Onko-Sure® assay pilot study measuring domestic cat serum suggests RPC's Onko-Sure® IVD cancer test may potentially detect cancer in domestic cats. In this pilot study, RPC ran samples from confirmed normal domestic cats and domestic cats with cancer. For cats with cancer, RPC ran a serum sample obtained first when the cats were cancer-free and another sample subsequently when the cats were confirmed with cancer. The relative levels of Onko-Sure® for the cats were compared using the Onko-Sure assay and showed a 2,853% increase in Onko-Sure levels versus the healthy sample. RPC is currently engaged in full clinical trial including 71 samples, which includes an antigen characterization that involves testing to identify direct evidence that RPC's Onko-Sure® IVD cancer test kits are effective in cancer detection in domestic felines.

According to Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals, "This development is anticipated to open the use of our Onko-Sure® assay as a veterinary cancer tool that could play an integral role in the screening and early detection of cancer for veterinary patients and further enhance RPC's strong portfolio of novel oncology products. This is truly an exciting development for the Company and our valued shareholders."

Onko‐Sure is a simple, non‐invasive, patent‐pending and regulatory‐approved IVD test for use as an aid in early detection of cancer. Onko‐Sure enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. Onko‐Sure is approved by the US FDA for the monitoring of colorectal cancer, Health Canada as a lung cancer screen and cancer monitoring tool, and the European Union, Indian government, Korean government, and Taiwanese government as a cancer monitoring or cancer screening test. Onko‐Sure test kits are currently sold as a blood test for cancer in Europe, India, Taiwan, Korea, and Vietnam and in Chili for research use.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring The company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • RPC Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    Tel: 206.310.5323